Relay Therapeutics, Inc.

Relay Therapeutics, Inc. (RLAY) priced its initial public offering on Jul 16, 2020 at $20.00 per share, raising $400M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $1.74B. J.P. Morgan was lead-left underwriter, joined by Goldman Sachs, TD Cowen and Guggenheim. Goodwin Procter advised the company and Ropes & Gray advised the underwriters.

Relay Therapeutics, Inc. is a clinical-stage precision medicines company applying its Dynamo platform, which integrates experimental and computational methods, to drug discovery based on protein structure and motion. It is advancing a pipeline initially focused on targeted oncology, aiming at protein targets previously considered hard to drug.

Status

IPO

Ticker

RLAY

Exchange

Nasdaq Global Market

Priced

Jul 16, 2020

IPO price

$20.00

Raised

$400M

Market cap at IPO price

$1.74B

First filed

Jun 24, 2020

Underwriters

J.P. Morgan, Goldman Sachs, TD Cowen and Guggenheim

Company counsel

Goodwin Procter

Underwriters' counsel

Ropes & Gray

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.